MA
CNCR

Montag & Associates’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Montag & Associates’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed – – 956
2022
Q3 		$0 Hold
3
– – ﹤0.01% 871
2022
Q2 		$0 Hold
3
– – ﹤0.01% 832
2022
Q1 		$0 Hold
3
– – ﹤0.01% 852
2021
Q4 		$0 Hold
3
– – ﹤0.01% 864
2021
Q3 		$0 Hold
3
– – ﹤0.01% 871
2021
Q2 		$0 Hold
3
– – ﹤0.01% 864
2021
Q1 		$0 Buy
+3
New +$98 ﹤0.01% 867

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Montag & Associates's CNCR Position: Q4 2022 in Review

Montag & Associates sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2022, closing a stake of 3 shares.

Montag & Associates first reported a position in CNCR in Q1 2021 and held it in 7 quarters. The position peaked at $0 in Q3 2022. 20 funds tracked by Wall St. Rank hold CNCR as of Q4 2022.

  • Montag & Associates reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2022 after selling out during the quarter.
  • Montag & Associates sold 3 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2022.
  • Montag & Associates first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2021 and held it in 7 quarters.
  • Montag & Associates's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $0 in Q3 2022.
  • 20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2022.

Based on Montag & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.